ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
5-Methoxyflavone inhibits the proliferation of lung adenocarcinoma cells through PI3K/AKT/GSK3β/β-catenin/Cyclin D1 signaling and attenuates chemoresistance and PD-L1 expression.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tangeretin Suppresses LUAD via SSTR4 Downregulation: Integrated Bioinformatics and Functional Validation.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
5-Methoxyflavone, a natural flavonoid compound, has been shown to exhibit pro-apoptotic effects in certain types of cancer. However, its function in lung adenocarcinoma (LUAD) is not known. This study is designed to investigate the anti-tumor effect of 5-methoxyflavone on LUAD. In vitro and in vivo experiments were performed to examine the impact of 5-methoxyflavone on the proliferation of LUAD cells. The target and biological activities of 5-methoxyflavone against LUAD were predicted by bioinformatics analysis. The effect of 5-methoxyflavone on cisplatin resistance was assessed by MTT and RT-qPCR. The programmed death-ligand 1 (PD-L1) expression was determined by western blot and immunofluorescence. 5-Methoxyflavone significantly inhibited the proliferation of LUAD cells by inducing G0/G1-phase arrest. Moreover, it suppressed tumor growth in a xenograft mouse model without causing organ toxicity. Mechanistic studies revealed that 5-methoxyflavone induced proteasomal degradation of cyclin D1 through inactivation of phosphoinositide 3-kinase/protein kinase B/glycogen synthase kinase-3β (PI3K/AKT/GSK3β) signaling. The addition of the AKT activator SC79 or the GSK3β inhibitor SB216763 reversed the reduction of cyclin D1 expression. Furthermore, 5-methoxyflavone might decrease the transcriptional level of cyclin D1 via downregulation of β-catenin expression (substrate of GSK3β). A combination of 5-methoxyflavone and cisplatin acted synergistically to overcome cisplatin resistance and reduced mRNA expression of resistant-associated genes in LUAD cells. Remarkably, 5-methoxyflavone hindered phosphorylation activation of STAT3, thus inhibiting PD-L1 expression in LUAD cells. In summary, we elucidated the anti-proliferative, chemo-sensitizing, and immunomodulatory effects of 5-methoxyflavone against LUAD, providing a potential new drug for the treatment of LUAD.
Indexed as
Identifiers
41168435What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.